Peking UFH
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
Location contact
Di Song, PhD
CONTACT
Yuqing Chen, PhD
CONTACT
NCT Number: NCT06975995
The purpose of the trial is to explore the effect of exogenous postbiotics supply on the quality of life and nutritional status of elderly hemodialysis patients.
Participants will be devided into intervention group and placebo group in an 1:1 ratio.They will:
1. In the treatment period for 12 weeks, intervention group receives postbiotics product while the other group receives placebo. 2. In the subsequent 12 weeks, intervention group ends the trial and placebo group enters into remedial treatment period. Placebo group will receive postbiotics product for 12 weeks.
Researchers will analyze the change of indicators such as quality of life and nutrition state of participants from the baseline to end of treatment, and compare the difference between the two group.
Interested in participating?
Request Info65 year and older
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
Di Song, PhD
CONTACT
Yuqing Chen, PhD
CONTACT
Intestinal flora imbalance has a high prevalence in CKD patients and is closely invloved with CKD complications like malnutrition and anemia, which affects quality of life and long-term prognosis of CKD patients. Probiotics is the bioactive compound produced by probiotics when it consumes prebiotics. It can alleviate the condition and improve quality of life of patients by regulating growth of microbiota directly and indirectly and inhibiting growth of pathogenic microorganism. The purpose of the trial is to explore the effect of exogenous postbiotics supply on the quality of life and nutritional status of elderly hemodialysis patients.
The study is a multicenter prospective open-labled and randomized controlled trial. Elderly patients with age ≥65 years and received hemodialysis treatment for more than 6 months will be included in the study. During the screen period, the patients with medical history that might affect oral feeding or gastrointestinal functions will be excluded.
After enrollment, the patients will be educated about how to keep diet records and then they will be randomly divided into group A (intervention group) and group B (placebo group) in an 1:1 ratio. The patients in group A will receive oral postbiotics and group B receive placebo. The treatment period is 12 weeks. Subsequently, group A ends the trial, and group B enters the remedial treatment period, receiving oral postbiotics, and the treatment cycle is 12 weeks.
At 0, 12 and 24 weeks quality of life score, nutrition evaluation, diet status and gastrointestinal symptom score respectively will be evaluated. The stool and serum of patients will be collected for intestinal flora and urotoxins measurements. Besides, the trial will collect routine biochemical indicators. The investigators will analyze those indicators above from the baseline to end of treatment and compare the difference between intervention group and placebo group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Investigators must maintain a screening log of all potential study candidates that includes limited information about the potential candidate, date, and outcome of the screening process (e.g. enrolled into study, reason for ineligibility, or refused to participate). After signing an informed consent form, potential patients must meet all of the criteria:
Exclusion criteria
The following exclusion criteria must NOT be present for each subject:
The oral postbiotics product used in the trial is called Yi'en Yuan Honey Fermented Drink. The product is made from water, edible brown sugar, and honey as raw materials. It is fermented by a mixture of plant lactic acid bacteria and coagulating Bacillus, and then inactivated at high temperature. The product meets the food and beverage standard. Participants will receive the product for 150ml per day.
Time frame: baseline, the 12th week of treatment period
Nutritional status of the patient is defined as the results of physical examination and SGA-7 rating scale.
Time frame: baseline, the 12th week of treatment period
Gastrointestinal symptoms of the patient is defined as the scores of gastrointestinal symptom rating scale (GSRS).
Time frame: baseline, the 12th week of treatment period
Quality of life of the patient is defined as the scores of kidney disease life quality scale (SF-36) .
Time frame: baseline, the 12th week of treatment period
Asthenia of the patients is defined as the scores of edmonton frail Scale (EFS).
Time frame: baseline, the 12th week of treatment period
The BMI (kg/m2) of the patients.
Time frame: baseline, the 12th week of treatment period
The dry weight of the patient is obtained from the bioelectrical impedance analysis.
Time frame: baseline, the 12th week of treatment period
Enterogenous urotoxin level is defined as the serum level of IS. The levels of serum IS will be measured by mass spectrometry.
Time frame: baseline, the 12th week of treatment period
Enterogenous urotoxin level is defined as the serum level of TMAO. The levels of serum TMAO will be measured by mass spectrometry.
Time frame: baseline, the 12th week of treatment period
Enterogenous urotoxin level is defined as the serum level of PCS. The levels of serum PCS will be measured by mass spectrometry.
Time frame: baseline, the 12th week of treatment period
The levels of hemogolbin (g/L).
Time frame: baseline, the 12th week of treatment period
The levels of albumin (g/L)
Time frame: baseline, the 12th week of treatment period
The levels of BUN (mmol/L).
Contact information is provided by the study sponsor or research team.
Peking University First Hospital
Other
A Postbiotics Improves the Quality of Life and Nutritional Status in Elderly Hemodialysis Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07591714
Chronic Disease, Disease Attributes
Isfahan, Iran
View Trial DetailsNCT07512895
Behavior, Behavioral Symptoms
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07206524
Blood Coagulation Disorders, Cardiovascular Diseases
Brussels, Belgium
View Trial DetailsNCT07047547
Cardiovascular Diseases, Heart Diseases
Guangzhou, Guangdong, China
View Trial Details